US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Bicara Therapeutics

16.24

-0.1600-0.98%

Post-market: 16.520.2800+1.72%16:47 EST

Volume:220.34K

Turnover:3.60M

Market Cap:889.66M

PE:-7.29

High:16.66

Open:16.49

Low:16.20

Close:16.40

52wk High:19.71

52wk Low:7.80

Shares:54.78M

Float Shares:24.13M

Volume Ratio:0.37

T/O Rate:0.91%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-2.2271

EPS(LYR):-4.0460

ROE:-26.64%

ROA:-18.59%

PB:2.21

PE(LYR):-4.01

Loading ...

Overview Company News Filings

Bicara Therapeutics Chief Medical Officer David Raben Reports Disposal of Common Shares

Bicara Therapeutics (BCAX): A Fresh Valuation Check After Q3 Earnings Reveal Sharp Shift in Losses

Simply Wall St.

Stock Track | Bicara Therapeutics Soars 5.03% as Multiple Analysts Boost Price Targets

Stock Track | Bicara Therapeutics Soars 5% as Multiple Analysts Boost Price Targets

Bicara Therapeutics Is Maintained at Equal-Weight by Wells Fargo

H.C. Wainwright Remains a Buy on Bicara Therapeutics Inc. (BCAX)

Promising Drug Pipeline and Upcoming Trial Data Support Buy Rating for Bicara Therapeutics

Bicara Therapeutics Q3 EPS $(0.67) Misses $(0.54) Estimate

Bicara Therapeutics reports Q3 EPS (67c), consensus (53c)

Bicara Therapeutics reports third quarter net loss of $36.3 million

Bicara Therapeutics Inc: Net Loss Totaled $36.3 Mln for Q3 2025

THOMSON REUTERS

Bicara Therapeutics: Expects Its Existing Cash, Cash Equivalents and Investments Will Fund Operations Into the First Half of 2029

THOMSON REUTERS

Bicara Therapeutics publishes data on dual targeting of TGF-β and EGFR with ficerafusp alfa in KRAS/BRAF wild-type MSS colorectal cancer

Bicara Therapeutics Inc. Publishes Study on Molecular Profiling and Spatial Transcriptomics in HNSCC

Bicara Therapeutics’ Innovative Approach to EGFR-Driven Tumors: A Clinical Study Update

Bicara Therapeutics CEO Claire Mazumdar Reports Disposal of Common Shares

Bicara Therapeutics: Strategic Advantages and Favorable Safety Profile Drive Buy Rating

Bicara sinks after J&J reports head and neck cancer data

JonesTrading Keeps Their Buy Rating on Bicara Therapeutics Inc. (BCAX)

Bicara Therapeutics CEO Claire Mazumdar Reports Disposal of Common Shares

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/BCAX/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BCAX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BCAX\",,,,,undefined,":{"symbol":"BCAX","market":"US","secType":"STK","nameCN":"Bicara Therapeutics","latestPrice":16.24,"timestamp":1771966800000,"preClose":16.4,"halted":0,"volume":220342,"hourTrading":{"tag":"盘后","latestPrice":16.52,"preClose":16.24,"latestTime":"16:47 EST","volume":14067,"amount":227119.719123,"timestamp":1771969645842,"change":0.28,"changeRate":0.017241,"amplitude":0.068966},"delay":0,"changeRate":-0.009756097560975618,"floatShares":24134001,"shares":54781950,"eps":-2.227112,"marketStatus":"Post-Mkt","change":-0.16,"latestTime":"02-24 19:11:58 EST","open":16.49,"high":16.66,"low":16.2,"amount":3602397.138014,"amplitude":0.028049,"askPrice":18,"askSize":400,"bidPrice":16.2,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-2.227112,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1771981200000},"marketStatusCode":4,"adr":0,"listingDate":1726200000000,"exchange":"NASDAQ","adjPreClose":16.4,"postHourTrading":{"tag":"盘后","latestPrice":16.52,"preClose":16.24,"latestTime":"16:47 EST","volume":14067,"amount":227119.719123,"timestamp":1771969645842,"change":0.28,"changeRate":0.017241,"amplitude":0.068966},"volumeRatio":0.366421,"impliedVol":0.0688,"impliedVolPercentile":0.0359},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BCAX\",,,,,undefined,":{"symbol":"BCAX","floatShares":24134001,"roa":"-18.59%","roe":"-26.64%","lyrEps":-4.045991,"volumeRatio":0.366421,"shares":54781950,"dividePrice":0,"high":16.66,"amplitude":0.028049,"preClose":16.4,"low":16.2,"week52Low":7.8,"pbRate":"2.21","week52High":19.71,"institutionHeld":0,"latestPrice":16.24,"committee":-0.6,"eps":-2.227112,"divideRate":0,"volume":220342,"delay":0,"ttmEps":-2.227112,"open":16.49,"prevYearClose":16.83,"prevWeekClose":15.48,"prevMonthClose":16.8,"prevQuarterClose":16.83,"fiveDayClose":14.08,"twentyDayClose":16.42,"sixtyDayClose":18.46},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BCAX\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-11-10","symbol":"BCAX","fiscalQuarterEnding":"2025/09","expectedEps":-0.55,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1762750800000,"reportTimeType":"pre","actualEps":-0.67},{"market":"US","date":"2025-08-12","symbol":"BCAX","fiscalQuarterEnding":"2025/06","expectedEps":-0.54,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1754971200000,"reportTimeType":"pre","actualEps":-0.5},{"market":"US","date":"2025-05-13","symbol":"BCAX","fiscalQuarterEnding":"2025/03","expectedEps":-0.4,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1747108800000,"reportTimeType":"pre","actualEps":-0.68},{"market":"US","date":"2025-03-27","symbol":"BCAX","fiscalQuarterEnding":"2024/12","expectedEps":-0.31,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1743048000000,"reportTimeType":"pre","actualEps":-0.39},{"market":"US","date":"2024-11-12","symbol":"BCAX","fiscalQuarterEnding":"2024/09","expectedEps":-0.46,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1731387600000,"reportTimeType":"pre","actualEps":-1.6}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BCAX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"BCAX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.2308,"buy":0.5385,"hold":0.2308,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5385,"analysts":13,"updateTime":1771045200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/BCAX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"BCAX","date":"2026-02-23","current":-7.363797,"percent":0.716667,"low":-22.704836,"twenty":-15.55307,"median":-8.82703,"eighty":-6.531258,"high":-5.144536,"avg":-10.646057,"sd":4.725718,"marketCap":848024586},"quantilePoints":[{"date":"2024-09-13","current":-12.837909,"twenty":-12.837909,"median":-12.837909,"eighty":-12.837909,"marketCap":832435719},{"date":"2024-09-20","current":-20.633135,"twenty":-21.391361,"median":-20.283845,"eighty":-14.007791,"marketCap":1337893755},{"date":"2024-09-27","current":-21.555755,"twenty":-21.594337,"median":-21.446718,"eighty":-19.006626,"marketCap":1397718272},{"date":"2024-10-04","current":-19.962139,"twenty":-21.575885,"median":-21.337681,"eighty":-19.559541,"marketCap":1294385015},{"date":"2024-10-11","current":-15.936161,"twenty":-21.540658,"median":-20.570229,"eighty":-18.732598,"marketCap":1033332575},{"date":"2024-10-18","current":-17.143955,"twenty":-21.466848,"median":-20.283845,"eighty":-16.808457,"marketCap":1111648307},{"date":"2024-10-25","current":-18.964032,"twenty":-21.403103,"median":-19.23243,"eighty":-16.959431,"marketCap":1229665764},{"date":"2024-10-31","current":-19.878264,"twenty":-21.362844,"median":-19.23243,"eighty":-17.02653,"marketCap":1288946422},{"date":"2024-11-08","current":-19.79439,"twenty":-21.337681,"median":-19.82794,"eighty":-17.143955,"marketCap":1283507830},{"date":"2024-11-15","current":-20.345116,"twenty":-21.127995,"median":-19.949558,"eighty":-18.418848,"marketCap":1210086831},{"date":"2024-11-22","current":-16.257533,"twenty":-21.102833,"median":-19.82794,"eighty":-17.143955,"marketCap":966965549},{"date":"2024-11-29","current":-19.02049,"twenty":-20.975343,"median":-19.458892,"eighty":-17.009755,"marketCap":1131300719},{"date":"2024-12-06","current":-17.876882,"twenty":-20.695202,"median":-19.01323,"eighty":-17.12047,"marketCap":1063281195},{"date":"2024-12-13","current":-16.509127,"twenty":-20.532485,"median":-19.005969,"eighty":-17.12047,"marketCap":981929844},{"date":"2024-12-20","current":-15.187116,"twenty":-20.493904,"median":-18.892739,"eighty":-16.769874,"marketCap":903299275},{"date":"2024-12-27","current":-17.49263,"twenty":-20.458153,"median":-18.854995,"eighty":-16.764842,"marketCap":1040426635},{"date":"2025-01-03","current":-15.484454,"twenty":-20.399979,"median":-18.727694,"eighty":-16.641786,"marketCap":920984351},{"date":"2025-01-10","current":-13.952019,"twenty":-20.332862,"median":-18.565256,"eighty":-16.325863,"marketCap":829838189},{"date":"2025-01-17","current":-10.868852,"twenty":-20.271506,"median":-18.306879,"eighty":-15.951961,"marketCap":646457553},{"date":"2025-01-24","current":-10.951191,"twenty":-20.22215,"median":-18.224539,"eighty":-15.55307,"marketCap":651354959},{"date":"2025-01-31","current":-11.811185,"twenty":-20.138275,"median":-17.666458,"eighty":-14.949245,"marketCap":702505641},{"date":"2025-02-07","current":-11.52757,"twenty":-20.11652,"median":-17.561246,"eighty":-13.156068,"marketCap":685636799},{"date":"2025-02-14","current":-12.003311,"twenty":-19.978914,"median":-17.49263,"eighty":-12.003311,"marketCap":713932921},{"date":"2025-02-21","current":-12.643731,"twenty":-19.965494,"median":-17.085242,"eighty":-11.997822,"marketCap":752023854},{"date":"2025-02-28","current":-11.307997,"twenty":-19.942009,"median":-16.815614,"eighty":-11.891694,"marketCap":672577050},{"date":"2025-03-07","current":-14.409462,"twenty":-19.890007,"median":-16.73236,"eighty":-11.891694,"marketCap":857045999},{"date":"2025-03-14","current":-12.213735,"twenty":-19.838005,"median":-16.60519,"eighty":-11.893524,"marketCap":726448513},{"date":"2025-03-21","current":-11.975864,"twenty":-19.8011,"median":-16.394587,"eighty":-11.882546,"marketCap":712300452},{"date":"2025-03-28","current":-10.745093,"twenty":-19.525992,"median":-16.092853,"eighty":-11.882546,"marketCap":730612568},{"date":"2025-04-04","current":-9.486153,"twenty":-19.364339,"median":-15.936742,"eighty":-11.721526,"marketCap":645010946},{"date":"2025-04-11","current":-8.139007,"twenty":-19.311424,"median":-15.55307,"eighty":-11.500123,"marketCap":553411758},{"date":"2025-04-17","current":-9.430022,"twenty":-19.133936,"median":-15.269456,"eighty":-11.355571,"marketCap":641194313},{"date":"2025-04-25","current":-12.533268,"twenty":-19.02049,"median":-15.045308,"eighty":-11.297018,"marketCap":852199585},{"date":"2025-05-02","current":-11.795546,"twenty":-19.011777,"median":-14.409462,"eighty":-11.329955,"marketCap":802038125},{"date":"2025-05-09","current":-10.531076,"twenty":-18.980807,"median":-14.002338,"eighty":-11.242349,"marketCap":716060542},{"date":"2025-05-16","current":-8.546663,"twenty":-18.933837,"median":-13.265854,"eighty":-11.091295,"marketCap":789139074},{"date":"2025-05-23","current":-9.249533,"twenty":-18.888545,"median":-12.837909,"eighty":-10.95668,"marketCap":854037173},{"date":"2025-05-30","current":-5.575709,"twenty":-18.86506,"median":-12.634583,"eighty":-10.80298,"marketCap":514821897},{"date":"2025-06-06","current":-6.514837,"twenty":-18.854995,"median":-12.506498,"eighty":-10.643069,"marketCap":601534484},{"date":"2025-06-13","current":-6.833787,"twenty":-18.81138,"median":-12.341819,"eighty":-10.421008,"marketCap":630984042},{"date":"2025-06-20","current":-5.569802,"twenty":-18.738652,"median":-12.190862,"eighty":-10.145292,"marketCap":514276535},{"date":"2025-06-27","current":-5.203601,"twenty":-18.705007,"median":-12.094799,"eighty":-9.441248,"marketCap":480464080},{"date":"2025-07-03","current":-5.333543,"twenty":-18.687321,"median":-12.003311,"eighty":-9.12531,"marketCap":492462048},{"date":"2025-07-11","current":-5.859219,"twenty":-18.443191,"median":-11.975864,"eighty":-8.617541,"marketCap":540999282},{"date":"2025-07-18","current":-6.881039,"twenty":-18.418848,"median":-11.920971,"eighty":-8.339475,"marketCap":635346939},{"date":"2025-07-25","current":-7.04642,"twenty":-18.306879,"median":-11.898098,"eighty":-7.625808,"marketCap":650617080},{"date":"2025-08-01","current":-6.562089,"twenty":-18.251986,"median":-11.884376,"eighty":-7.016887,"marketCap":605897381},{"date":"2025-08-08","current":-6.0246,"twenty":-18.224539,"median":-11.847781,"eighty":-6.881039,"marketCap":556269423},{"date":"2025-08-15","current":-6.063601,"twenty":-17.876882,"median":-11.795546,"eighty":-6.786535,"marketCap":622562015},{"date":"2025-08-22","current":-6.180515,"twenty":-17.675607,"median":-11.648291,"eighty":-6.638873,"marketCap":634565840},{"date":"2025-08-29","current":-6.329315,"twenty":-17.657309,"median":-11.619058,"eighty":-6.514837,"marketCap":649843436},{"date":"2025-09-05","current":-6.409029,"twenty":-17.584119,"median":-11.52757,"eighty":-6.407746,"marketCap":658027862},{"date":"2025-09-12","current":-6.366515,"twenty":-17.562161,"median":-11.3858,"eighty":-6.401771,"marketCap":653662835},{"date":"2025-09-19","current":-5.877601,"twenty":-17.506353,"median":-11.36289,"eighty":-6.371769,"marketCap":603465021},{"date":"2025-09-26","current":-5.686286,"twenty":-17.49263,"median":-11.294273,"eighty":-6.328252,"marketCap":583822398},{"date":"2025-10-03","current":-8.880173,"twenty":-17.49263,"median":-11.226216,"eighty":-6.328252,"marketCap":911745073},{"date":"2025-10-10","current":-9.712715,"twenty":-17.21369,"median":-11.089726,"eighty":-6.337818,"marketCap":997223830},{"date":"2025-10-17","current":-9.936118,"twenty":-17.050015,"median":-11.051829,"eighty":-6.344195,"marketCap":1020161070},{"date":"2025-10-24","current":-8.999952,"twenty":-16.959431,"median":-10.928319,"eighty":-6.362264,"marketCap":924043110},{"date":"2025-10-31","current":-8.755273,"twenty":-16.841022,"median":-10.759065,"eighty":-6.371769,"marketCap":898921371},{"date":"2025-11-07","current":-7.749959,"twenty":-16.783048,"median":-10.701761,"eighty":-6.376332,"marketCap":795703789},{"date":"2025-11-14","current":-6.428441,"twenty":-16.754777,"median":-10.617258,"eighty":-6.376332,"marketCap":781190607},{"date":"2025-11-21","current":-7.293982,"twenty":-16.72193,"median":-10.425573,"eighty":-6.385646,"marketCap":886371951},{"date":"2025-11-28","current":-8.366891,"twenty":-16.703998,"median":-10.156917,"eighty":-6.394149,"marketCap":1016752992},{"date":"2025-12-05","current":-8.457052,"twenty":-16.641786,"median":-10.005266,"eighty":-6.400929,"marketCap":1027709382},{"date":"2025-12-12","current":-8.497624,"twenty":-16.572254,"median":-9.798232,"eighty":-6.406463,"marketCap":1032639757},{"date":"2025-12-19","current":-7.952153,"twenty":-16.525595,"median":-9.707395,"eighty":-6.409029,"marketCap":966353598},{"date":"2025-12-26","current":-7.785356,"twenty":-16.417495,"median":-9.581658,"eighty":-6.416794,"marketCap":946084276},{"date":"2026-01-02","current":-7.587003,"twenty":-16.275544,"median":-9.536519,"eighty":-6.433907,"marketCap":921980218},{"date":"2026-01-09","current":-7.465287,"twenty":-16.224597,"median":-9.44371,"eighty":-6.465223,"marketCap":907189092},{"date":"2026-01-16","current":-7.523891,"twenty":-16.076385,"median":-9.207398,"eighty":-6.505387,"marketCap":914310745},{"date":"2026-01-23","current":-7.929613,"twenty":-16.010514,"median":-9.12531,"eighty":-6.514837,"marketCap":963614500},{"date":"2026-01-30","current":-7.623067,"twenty":-15.937323,"median":-9.082399,"eighty":-6.531258,"marketCap":926362774},{"date":"2026-02-06","current":-6.807115,"twenty":-15.936161,"median":-9.042505,"eighty":-6.562089,"marketCap":827207445},{"date":"2026-02-13","current":-6.338281,"twenty":-15.928174,"median":-8.933537,"eighty":-6.562089,"marketCap":770234217},{"date":"2026-02-20","current":-6.951372,"twenty":-15.628091,"median":-8.853601,"eighty":-6.527974,"marketCap":844737669},{"date":"2026-02-23","current":-6.97842,"twenty":-15.55307,"median":-8.82703,"eighty":-6.531258,"marketCap":848024586}],"updateTime":1771941754389},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BCAX\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2586407231","title":"Bicara Therapeutics Chief Medical Officer David Raben Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2586407231","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586407231?lang=en_us&edition=fundamental","pubTime":"2025-11-26 07:40","pubTimestamp":1764114022,"startTime":"0","endTime":"0","summary":"David Raben, Chief Medical Officer of Bicara Therapeutics Inc., reported a disposal of common shares of Bicara Therapeutics Inc. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bicara Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 25, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251125:nNDL20y0V0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Bicara Therapeutics Chief Medical Officer David Raben Reports Disposal of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCAX","BK4139"],"gpt_icon":0},{"id":"2586163744","title":"Bicara Therapeutics (BCAX): A Fresh Valuation Check After Q3 Earnings Reveal Sharp Shift in Losses","url":"https://stock-news.laohu8.com/highlight/detail?id=2586163744","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586163744?lang=en_us&edition=fundamental","pubTime":"2025-11-25 07:14","pubTimestamp":1764026048,"startTime":"0","endTime":"0","summary":"Bicara Therapeutics (BCAX) just released its earnings report for the third quarter and nine months through September 2025, revealing sharp changes in both net loss and basic loss per share compared to last year.\nSee our latest analysis for Bicara Therapeutics.\nThe latest share price surge, up 11.5% in a single day and 19.9% over the past week, signals renewed momentum for Bicara Therapeutics. However, with a total shareholder return of -1.2% over the past year, longer-term investors have not...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-bcax/bicara-therapeutics/news/bicara-therapeutics-bcax-a-fresh-valuation-check-after-q3-ea","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-bcax/bicara-therapeutics/news/bicara-therapeutics-bcax-a-fresh-valuation-check-after-q3-ea","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BCAX"],"gpt_icon":0},{"id":"1124620838","title":"Stock Track | Bicara Therapeutics Soars 5.03% as Multiple Analysts Boost Price Targets","url":"https://stock-news.laohu8.com/highlight/detail?id=1124620838","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1124620838?lang=en_us&edition=fundamental","pubTime":"2025-11-11 23:24","pubTimestamp":1762874659,"startTime":"0","endTime":"0","summary":"Bicara Therapeutics (BCAX) stock is soaring 5.03% in Tuesday's trading session, buoyed by a series of positive analyst ratings and increased price targets. The biotechnology company has caught the...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["BCAX"],"gpt_icon":0},{"id":"1152698193","title":"Stock Track | Bicara Therapeutics Soars 5% as Multiple Analysts Boost Price Targets","url":"https://stock-news.laohu8.com/highlight/detail?id=1152698193","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1152698193?lang=en_us&edition=fundamental","pubTime":"2025-11-11 23:24","pubTimestamp":1762874657,"startTime":"0","endTime":"0","summary":"Shares of Bicara Therapeutics (BCAX) are soaring 5.03% in Tuesday's trading session, fueled by a series of positive analyst actions. The biotechnology company has caught the attention of Wall Street,...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["BCAX"],"gpt_icon":0},{"id":"2582367021","title":"Bicara Therapeutics Is Maintained at Equal-Weight by Wells Fargo","url":"https://stock-news.laohu8.com/highlight/detail?id=2582367021","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582367021?lang=en_us&edition=fundamental","pubTime":"2025-11-11 22:46","pubTimestamp":1762872360,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/BCAX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 11, 2025 09:46 ET (14:46 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1363072403.SGD","BCAX","LU0048573561.USD","BK4501","LU0320765489.SGD","IE0002270589.USD","LU2461242641.AUD","BK4139","LU0648001328.SGD","LU0868494617.USD","LU0289960550.SGD","LU0640476718.USD","LU0708994859.HKD","LU1814569148.SGD","IE00B19Z3581.USD","LU0162691827.USD","LU0149725797.USD","LU1267930227.SGD","LU1074936037.SGD","LU0072461881.USD","IE000M9KFDE8.USD","LU0106831901.USD","LU0256863811.USD","LU0267386448.USD","LU0208291251.USD","IE00B19Z3B42.SGD","LU0942090050.USD","LU0310800965.SGD","LU0029864427.USD","LU2361044949.HKD","LU0742534661.SGD","BK4559","LU0130517989.USD","LU0971096721.USD","BK4504","BK4585","BK4207","LU1035773651.USD","LU1506573853.SGD","LU0251142724.SGD","LU0683600562.USD","LU0070302665.USD","LU0868494708.USD","LU1280957306.USD","LU0310800379.SGD","LU0175139822.USD","LU1668664300.SGD","LU1267930573.SGD","LU1267930490.SGD","LU0251131958.USD"],"gpt_icon":0},{"id":"2582636518","title":"H.C. Wainwright Remains a Buy on Bicara Therapeutics Inc. (BCAX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2582636518","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582636518?lang=en_us&edition=fundamental","pubTime":"2025-11-11 19:56","pubTimestamp":1762862185,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Robert Burns reiterated a Buy rating on Bicara Therapeutics Inc. today and set a price target of $40.00. Burns covers the H...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-remains-a-buy-on-bicara-therapeutics-inc-bcax-blurbs-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-remains-a-buy-on-bicara-therapeutics-inc-bcax-blurbs-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BCAX","BK4139"],"gpt_icon":0},{"id":"2582318388","title":"Promising Drug Pipeline and Upcoming Trial Data Support Buy Rating for Bicara Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2582318388","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582318388?lang=en_us&edition=fundamental","pubTime":"2025-11-11 05:15","pubTimestamp":1762809314,"startTime":"0","endTime":"0","summary":"Analyst Soumit Roy of JonesTrading maintained a Buy rating on Bicara Therapeutics Inc., retaining the price target of $27.00. Soumit Roy has given ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/promising-drug-pipeline-and-upcoming-trial-data-support-buy-rating-for-bicara-therapeutics-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/promising-drug-pipeline-and-upcoming-trial-data-support-buy-rating-for-bicara-therapeutics-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BCAX"],"gpt_icon":0},{"id":"2582876166","title":"Bicara Therapeutics Q3 EPS $(0.67) Misses $(0.54) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2582876166","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582876166?lang=en_us&edition=fundamental","pubTime":"2025-11-10 20:41","pubTimestamp":1762778517,"startTime":"0","endTime":"0","summary":"Bicara Therapeutics (NASDAQ:BCAX) reported quarterly losses of $(0.67) per share which missed the analyst consensus estimate of $(0.54) by 23.84 percent. This is a 58.13 percent increase over losses of $(1.60) per share","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/11/48748932/bicara-therapeutics-q3-eps-0-67-misses-0-54-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCAX"],"gpt_icon":0},{"id":"2582787696","title":"Bicara Therapeutics reports Q3 EPS (67c), consensus (53c)","url":"https://stock-news.laohu8.com/highlight/detail?id=2582787696","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582787696?lang=en_us&edition=fundamental","pubTime":"2025-11-10 20:37","pubTimestamp":1762778236,"startTime":"0","endTime":"0","summary":"“The FDA’s recent Breakthrough Therapy Designation for ficerafusp alfa in first-line HPV-negative HNSCC represents an important milestone for Bicar...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/bicara-therapeutics-reports-q3-eps-67c-consensus-53c-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/bicara-therapeutics-reports-q3-eps-67c-consensus-53c-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BCAX"],"gpt_icon":0},{"id":"2582875706","title":"Bicara Therapeutics reports third quarter net loss of $36.3 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2582875706","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582875706?lang=en_us&edition=fundamental","pubTime":"2025-11-10 20:30","pubTimestamp":1762777834,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bicara Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on November 10, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nNDLl0gsJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCAX","IE00BGHQF748.EUR","BK4588","BK4585","BK4139","BK4112","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","LU2210149790.SGD","NDAQ","LU2210150020.SGD","IE00BKPKM429.USD","LU0314104364.USD","LU2095319765.USD"],"gpt_icon":0},{"id":"2582987656","title":"Bicara Therapeutics Inc: Net Loss Totaled $36.3 Mln for Q3 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2582987656","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582987656?lang=en_us&edition=fundamental","pubTime":"2025-11-10 20:30","pubTimestamp":1762777801,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nTUA5NMWQT:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BCAX"],"gpt_icon":0},{"id":"2582987650","title":"Bicara Therapeutics: Expects Its Existing Cash, Cash Equivalents and Investments Will Fund Operations Into the First Half of 2029","url":"https://stock-news.laohu8.com/highlight/detail?id=2582987650","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582987650?lang=en_us&edition=fundamental","pubTime":"2025-11-10 20:30","pubTimestamp":1762777801,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nTUA5NMWQT:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BCAX","BK4139"],"gpt_icon":0},{"id":"2581464863","title":"Bicara Therapeutics publishes data on dual targeting of TGF-β and EGFR with ficerafusp alfa in KRAS/BRAF wild-type MSS colorectal cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2581464863","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581464863?lang=en_us&edition=fundamental","pubTime":"2025-11-08 23:10","pubTimestamp":1762614656,"startTime":"0","endTime":"0","summary":"Bicara Therapeutics publishes data on dual targeting of TGF-β and EGFR with ficerafusp alfa in KRAS/BRAF wild-type MSS colorectal cancer. Bicara Therapeutics Inc. published a document detailing research on dual targeting of TGF-β and EGFR in KRAS/BRAF wild-type MSS colorectal cancer cell lines. The document compares the antitumor activity of ficerafusp alfa with cetuximab and includes data on immune cell activity and tumor cytotoxicity. The full document can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bicara Therapeutics Inc. published the original content used to generate this news brief on November 08, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251108:nNDL6VpBV0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCAX","BK4139"],"gpt_icon":0},{"id":"2581776234","title":"Bicara Therapeutics Inc. Publishes Study on Molecular Profiling and Spatial Transcriptomics in HNSCC","url":"https://stock-news.laohu8.com/highlight/detail?id=2581776234","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581776234?lang=en_us&edition=fundamental","pubTime":"2025-11-05 22:43","pubTimestamp":1762353782,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bicara Therapeutics Inc. published the original content used to generate this news brief on November 05, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251105:nNDL42rx8J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TXG","BK4585","BCAX","BK4588","LU1861559042.SGD","LU1861558580.USD","BK4139","BK4548","BK4121"],"gpt_icon":0},{"id":"2578678982","title":"Bicara Therapeutics’ Innovative Approach to EGFR-Driven Tumors: A Clinical Study Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2578678982","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578678982?lang=en_us&edition=fundamental","pubTime":"2025-10-28 03:53","pubTimestamp":1761594792,"startTime":"0","endTime":"0","summary":"Bicara Therapeutics Inc. (($BCAX)) announced an update on their ongoing clinical study. Study Overview: Bicara Therapeutics Inc. is conducting a cl...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/bicara-therapeutics-innovative-approach-to-egfr-driven-tumors-a-clinical-study-update?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/bicara-therapeutics-innovative-approach-to-egfr-driven-tumors-a-clinical-study-update?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BCAX"],"gpt_icon":0},{"id":"2577989406","title":"Bicara Therapeutics CEO Claire Mazumdar Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2577989406","media":"Reuters","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577989406?lang=en_us&edition=fundamental","pubTime":"2025-10-21 07:10","pubTimestamp":1761001807,"startTime":"0","endTime":"0","summary":"Claire Mazumdar, Chief Executive Officer and Director of Bicara Therapeutics Inc., has reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bicara Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on October 20, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251020:nNDLcZ2Sz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCAX","BK4139"],"gpt_icon":0},{"id":"2577589500","title":"Bicara Therapeutics: Strategic Advantages and Favorable Safety Profile Drive Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2577589500","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577589500?lang=en_us&edition=fundamental","pubTime":"2025-10-21 04:55","pubTimestamp":1760993717,"startTime":"0","endTime":"0","summary":"Analyst Soumit Roy from JonesTrading reiterated a Buy rating on Bicara Therapeutics Inc. and keeping the price target at $27.00. Soumit Roy’s ratin...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/bicara-therapeutics-strategic-advantages-and-favorable-safety-profile-drive-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/bicara-therapeutics-strategic-advantages-and-favorable-safety-profile-drive-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BCAX"],"gpt_icon":0},{"id":"2577099861","title":"Bicara sinks after J&J reports head and neck cancer data","url":"https://stock-news.laohu8.com/highlight/detail?id=2577099861","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577099861?lang=en_us&edition=fundamental","pubTime":"2025-10-21 00:45","pubTimestamp":1760978711,"startTime":"0","endTime":"0","summary":"Shares of Bicara Therapeutics (BCAX) (BCRX) after moving lower after Johnson & Johnson (JNJ) reported Phase 1b/2 data for amivantamab in patients w...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/bicara-sinks-after-jj-reports-head-and-neck-cancer-data-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/bicara-sinks-after-jj-reports-head-and-neck-cancer-data-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00BJT1NW94.SGD","LU0122379950.USD","IE00BVYPNV92.GBP","LU0289739699.SGD","LU2471134796.USD","SG9999002224.SGD","BCRX","LU1066053197.SGD","LU2471134879.HKD","IE00BLSP4239.USD","LU1674673691.USD","LU1894683264.USD","LU2505996509.AUD","LU1496350502.SGD","LU0234572021.USD","BK4532","IE0002270589.USD","IE00BSNM7G36.USD","LU1935042991.SGD","IE00B19Z3B42.SGD","IE00BVYPNW00.USD","LU0320765646.SGD","LU1059921491.USD","BK4568","IE00BFTCPJ56.SGD","IE00B3T34201.USD","LU2129689605.HKD","LU0432979614.USD","LU0795875086.SGD","IE00B19Z3581.USD","LU0466842654.USD","LU1244550221.USD","BCAX","IE00BJJMRZ35.SGD","LU1732800096.USD","LU2112291526.USD","LU2750360641.GBP","LU2592432038.USD","LU2750360997.AUD","LU0203347892.USD","LU2430703251.USD","LU2468319806.SGD","LU1221951046.USD","LU2129689514.USD","LU0795875169.SGD","JNJ","LU1066051811.HKD","LU1585245621.USD","BK4585","LU1280957306.USD"],"gpt_icon":0},{"id":"2576320190","title":"JonesTrading Keeps Their Buy Rating on Bicara Therapeutics Inc. (BCAX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2576320190","media":"TIPRANKS","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576320190?lang=en_us&edition=fundamental","pubTime":"2025-10-17 19:55","pubTimestamp":1760702128,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Soumit Roy from JonesTrading reiterated a Buy rating on Bicara Therapeutics Inc., with a price target of $27.00. Th...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/jonestrading-keeps-their-buy-rating-on-bicara-therapeutics-inc-bcax-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/jonestrading-keeps-their-buy-rating-on-bicara-therapeutics-inc-bcax-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BCAX"],"gpt_icon":0},{"id":"2575752045","title":"Bicara Therapeutics CEO Claire Mazumdar Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2575752045","media":"Reuters","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575752045?lang=en_us&edition=fundamental","pubTime":"2025-10-16 06:01","pubTimestamp":1760565661,"startTime":"0","endTime":"0","summary":"Claire Mazumdar, Chief Executive Officer of Bicara Therapeutics Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bicara Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on October 15, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251015:nNDL5qCVwq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCAX","BK4139"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":3,"totalSize":76,"code":"91000000","status":"200"}]}}